Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength? [Yahoo! Finance]
Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.auriniapharma.com
Company Research
Source: Yahoo! Finance
This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7.3% loss over the past four weeks. The sudden soar in the stock price of the company is likely due to the positive momentum built around its pipeline. Aurinia's sole-marketed product, Lupkynis, is approved in the United States for the treatment of lupus nephritis. The product has witnessed solid uptake since its launch and is expected to perform well in the quarters ahead. Additionally, the company is also exploring alternative approaches for its pre-clinical candidate, AUR200. This biotechnology company is expected to post quarterly earnings of $0.01 per share in its upcoming report, which represents a year-over-year change of +112.5%. Revenues are expected to be $54.89 million, up 32.3% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical
Show less
Read more
Impact Snapshot
Event Time:
AUPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUPH alerts
High impacting Aurinia Pharmaceuticals Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
AUPH
News
- Aurinia Announces 2024 Annual General Meeting Results [Yahoo! Finance]Yahoo! Finance
- Aurinia Announces 2024 Annual General Meeting ResultsBusiness Wire
- We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO For Now [Yahoo! Finance]Yahoo! Finance
- ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal [Yahoo! Finance]Yahoo! Finance
- Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 [Yahoo! Finance]Yahoo! Finance
AUPH
Earnings
- 5/2/24 - Beat
AUPH
Sec Filings
- 6/14/24 - Form 8-K
- 6/4/24 - Form DEFA14A
- 6/4/24 - Form DEFA14A
- AUPH's page on the SEC website